Status:
RECRUITING
Vaccine-induced Immunity in Immunocompromised Patients
Lead Sponsor:
University of Cologne
Conditions:
Immunodeficiency
Eligibility:
All Genders
18+ years
Brief Summary
Managing respiratory virus infections in immunocompromised patients requires a multidisciplinary approach, including vaccination, though its effectiveness is often suboptimal in these individuals. In...
Detailed Description
Respiratory virus infections are a significant cause of morbidity and mortality, partic-ularly among immunocompromised patients. These infections are caused by a varie-ty of viral pathogens, including...
Eligibility Criteria
Inclusion
- Signed informed consent form
- Patients with immunosuppression either by treatment or underlying diseases
- Patients who are vaccinated or willing to be vaccinated against respiratory virus infections in ac-cordance with current recommendations
- Age of 18 years or older
Exclusion
- Patients unwilling/ineligible for vaccination under current recommendations
Key Trial Info
Start Date :
March 25 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2029
Estimated Enrollment :
5000 Patients enrolled
Trial Details
Trial ID
NCT06612515
Start Date
March 25 2025
End Date
December 31 2029
Last Update
March 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Cologne
Cologne, North Rhine-Westphalia, Germany, 50937